Polyester dendritic systems for drug delivery applications:: In vitro and in vivo evaluation

被引:416
作者
De Jesús, OLP
Ihre, HR
Gagne, L
Fréchet, JMJ
Szoka, FC
机构
[1] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA
关键词
D O I
10.1021/bc010103m
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
High molecular weight polymers (> 20 000 Da) have been widely used as soluble drug carriers to improve drug targeting and therapeutic efficacy. Dendritic polymers are exceptional candidates for the preparation of near monodisperse drug carriers due to their well-defined structure, multivalency, and flexibility for tailored functionalization. We evaluated various dendritic architectures composed of a polyester dendritic scaffold based on the monomer unit 2,2-bis(hydroxymethyl)propanoic acid for their suitability as drug carriers both in vitro and in vivo. These systems are both water soluble and nontoxic. In addition, the potent anticancer drug, doxorubicin, was covalently bound via a hydrazone linkage to a high molecular weight 3-arm poly(ethylene oxide)-dendrimer hybrid. Drug release was a function of pH, and the release rate was more rapid at pH < 6. The cytotoxicity of the DOX-polymer conjugate measured on multiple cancer lines in vitro was reduced but not eliminated, indicating that some active doxorubicin was released from the drug polymer conjugate under physiological conditions. Furthermore, biodistribution experiments show little accumulation of the DOX-polymer conjugate in vital organs, and the serum half-life of doxorubicin attached to an appropriate high molecular weight polymer has been significantly increased when compared to the free drug. Thus, this new macromolecular system exhibits promising characteristics for the development of new polymeric drug carriers.
引用
收藏
页码:453 / 461
页数:9
相关论文
共 47 条
  • [1] [Anonymous], ENZYME PRODRUG STRAT
  • [2] DOXORUBICIN-LOADED NANOSPHERES BYPASS TUMOR-CELL MULTIDRUG RESISTANCE
    CUVIER, C
    ROBLOTTREUPEL, L
    MILLOT, JM
    LIZARD, G
    CHEVILLARD, S
    MANFAIT, M
    COUVREUR, P
    POUPON, MF
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 44 (03) : 509 - 517
  • [3] DRUG POLYMER CONJUGATES - POTENTIAL FOR IMPROVED CHEMOTHERAPY
    DUNCAN, R
    [J]. ANTI-CANCER DRUGS, 1992, 3 (03) : 175 - 210
  • [4] Duncan R, 1996, STP PHARMA SCI, V6, P237
  • [5] Duncan R, 1996, CRS BUI NAT, P105
  • [6] Eliaz RE, 2001, CANCER RES, V61, P2592
  • [7] H+-INDUCED AND CA-2+-INDUCED FUSION AND DESTABILIZATION OF LIPOSOMES
    ELLENS, H
    BENTZ, J
    SZOKA, FC
    [J]. BIOCHEMISTRY, 1985, 24 (13) : 3099 - 3106
  • [8] Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
    Esfand, R
    Tomalia, DA
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (08) : 427 - 436
  • [9] Polyethylene glycol modification: Relevance of improved methodology to tumour targeting
    Francis, GE
    Delgado, C
    Fisher, D
    Malik, F
    Agrawal, AK
    [J]. JOURNAL OF DRUG TARGETING, 1996, 3 (05) : 321 - &
  • [10] FUNCTIONAL POLYMERS AND DENDRIMERS - REACTIVITY, MOLECULAR ARCHITECTURE, AND INTERFACIAL ENERGY
    FRECHET, JMJ
    [J]. SCIENCE, 1994, 263 (5154) : 1710 - 1715